Cyberattacks against healthcare organizations continue to rise and pharmacies remain attractive targets because they store and transmit large volumes of protected health information (PHI). As a result, the HIPAA Security Rule’s risk analysis requirement has become a primary enforcement priority for the Office for Civil Rights (OCR). Recent enforcement actions demonstrate that failing to perform and document a comprehensive risk analysis can be as costly as a cyber-attack itself. The recent June 18, 2026, OCR report marked the 20th Ransomware Enforcement Action and 14th Risk Analysis Initiative Enforcement Action with a settlement of $450,000 following a ransomware incident that affected just 10,000 individuals. OCR found that the organization failed to conduct an accurate and thorough risk analysis before the breach occurred and had not implemented appropriate compliance measures. In addition to the monetary settlement, the organization was required to complete a corrective action plan under federal oversight.
A HIPAA risk analysis is a required assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of electronic PHI (ePHI). According to HHS, a risk analysis is the foundation of Security Rule compliance and the first step in determining what safeguards are needed to protect patient information. Every covered entity (including pharmacies) must conduct an accurate and thorough assessment of its risks.
For pharmacies, a risk analysis should examine all systems and processes that create, receive, maintain, or transmit ePHI. This includes pharmacy management systems, dispensing software, point-of-sale systems, e-prescribing platforms, mobile devices, email, cloud applications, backups, and third-party vendors that have access to patient data. HHS emphasizes that organizations must identify where ePHI resides, understand how it flows through the organization, and evaluate threats ranging from ransomware and unauthorized access to natural disasters and accidental workforce errors.
A practical risk analysis generally includes several key steps, such as:
- An inventory of all locations where ePHI exists.
- Identifying potential threats and vulnerabilities.
- Assessing current security controls.
- Evaluating the likelihood and potential impact of each risk.
- Assigning risk levels and developing a written plan to address identified gaps.
This entire process must be documented, as OCR expects covered entities to produce written evidence of both the analysis and the resulting risk management activities. Just as important, a risk analysis is not a one-time exercise. OCR increasingly expects healthcare organizations to maintain a current assessment that reflects changes in technology, staffing, operations, remote access, and cyber threats. OCR enforcement actions repeatedly cite organizations that either never completed a risk analysis or failed to update one that had become outdated.
The consequences of neglecting this requirement can be significant. Not only may the pharmacy’s systems be vulnerable to internal and external threats, but OCR enforcement and settlements can be pricey. For pharmacies, the lesson is clear – cybersecurity and HIPAA compliance begins with understanding your risks. Pharmacies that can show they have identified risks, implemented safeguards, trained workforce members, and periodically reassessed their environment are in a far stronger position to protect patient data and defend their compliance efforts.
A robust HIPAA risk analysis is more than a regulatory requirement – it is an essential business practice.
PAAS Tips:
- The PAAS National® FWA/HIPAA Compliance Program provides pharmacies with numerous resources, including a step-by-step guide of the risk analysis process
- Although HIPAA does not mandate a specific review cycle, pharmacies should conduct and document a comprehensive risk analysis at least annually, and whenever significant operational, technological, or security changes occur.
HIPAA Security Risk Analysis: A Critical Compliance Obligation for Pharmacies
Cyberattacks against healthcare organizations continue to rise and pharmacies remain attractive targets because they store and transmit large volumes of protected health information (PHI). As a result, the HIPAA Security Rule’s risk analysis requirement has become a primary enforcement priority for the Office for Civil Rights (OCR). Recent enforcement actions demonstrate that failing to perform and document a comprehensive risk analysis can be as costly as a cyber-attack itself. The recent June 18, 2026, OCR report marked the 20th Ransomware Enforcement Action and 14th Risk Analysis Initiative Enforcement Action with a settlement of $450,000 following a ransomware incident that affected just 10,000 individuals. OCR found that the organization failed to conduct an accurate and thorough risk analysis before the breach occurred and had not implemented appropriate compliance measures. In addition to the monetary settlement, the organization was required to complete a corrective action plan under federal oversight.
A HIPAA risk analysis is a required assessment of the potential risks and vulnerabilities to the confidentiality, integrity, and availability of electronic PHI (ePHI). According to HHS, a risk analysis is the foundation of Security Rule compliance and the first step in determining what safeguards are needed to protect patient information. Every covered entity (including pharmacies) must conduct an accurate and thorough assessment of its risks.
For pharmacies, a risk analysis should examine all systems and processes that create, receive, maintain, or transmit ePHI. This includes pharmacy management systems, dispensing software, point-of-sale systems, e-prescribing platforms, mobile devices, email, cloud applications, backups, and third-party vendors that have access to patient data. HHS emphasizes that organizations must identify where ePHI resides, understand how it flows through the organization, and evaluate threats ranging from ransomware and unauthorized access to natural disasters and accidental workforce errors.
A practical risk analysis generally includes several key steps, such as:
This entire process must be documented, as OCR expects covered entities to produce written evidence of both the analysis and the resulting risk management activities. Just as important, a risk analysis is not a one-time exercise. OCR increasingly expects healthcare organizations to maintain a current assessment that reflects changes in technology, staffing, operations, remote access, and cyber threats. OCR enforcement actions repeatedly cite organizations that either never completed a risk analysis or failed to update one that had become outdated.
The consequences of neglecting this requirement can be significant. Not only may the pharmacy’s systems be vulnerable to internal and external threats, but OCR enforcement and settlements can be pricey. For pharmacies, the lesson is clear – cybersecurity and HIPAA compliance begins with understanding your risks. Pharmacies that can show they have identified risks, implemented safeguards, trained workforce members, and periodically reassessed their environment are in a far stronger position to protect patient data and defend their compliance efforts.
A robust HIPAA risk analysis is more than a regulatory requirement – it is an essential business practice.
PAAS Tips:
Topical Medication Billing: Accuracy Starts with the First Claim
Billing an accurate days’ supply on prescription claims is essential when it comes to avoiding audit issues. Inaccurate billing can lead to early refills that trigger audits and lead to recoupments. PBMs require pharmacies to calculate the days’ supply according to the instructions, and topical medications are no exception.
There can be several deciding factors when it comes to topical medication use.
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
Package Size Pitfalls: How PBM Auditors Are Scrutinizing Dispensing Practices
Prescription quantities must have a clear unit of measure to be sufficient for audit. Insulin pens and inhalers are just a couple of examples that auditor’s flag when the written quantity is vague or ambiguous. Clarifying with prescribers is often necessary to confirm mL, pens, boxes, etc. Without documentation to support the clarification, auditors will mark prescriptions discrepant, requiring additional work to retain payments.
The latest focus is …
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
What’s New with Prescription Validation Requests for 2026?
PBMs continually adjust their focus on which drugs they select for claim reviews. While most of the Prescription Validation Requests come from OptumRx, several other PBMs conduct them as well, albeit by other terminology (e.g., claim reviews). Below are the trends PAAS National® analysts have seen in the first half of 2026, starting with the top five drugs reviewed from January through June 2026, compared to the same time frame in 2025.
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
2026 DMEPOS Series #7: Therapeutic Shoes for Diabetics
Many pharmacies struggle with DMEPOS audits due to the complexity in medical billing and the onerous documentation requirements. Medicare Part B suppliers need to be able to produce all the required documentation if audited, and make sure all documentation meets Medicare Part B standards. This DMEPOS series is intended to help you understand these complexities and gather the needed documents.
The following documentation is required upon an audit for therapeutic shoes for diabetics:
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
Supermarket Pharmacy Chain Pays $40 Million Over Usual & Customary Violations
A recent $40 million settlement involving Ahold Delhaize USA Inc. is serving as another reminder that pharmacy pricing practices, particularly Usual & Customary (U&C) pricing, remain under significant regulatory scrutiny.
The company, which operates grocery-store pharmacies under banners including Giant, Hannaford, Stop & Shop, and Food Lion, agreed to resolve allegations that it submitted inflated U&C prices on claims to Medicare Part D, Medicaid, and TRICARE.
According to the government, Ahold pharmacies offered prescription savings programs that provided discounted drug pricing to enrolled customers. Regulators alleged those lower prices should have been reported as the pharmacy’s U&C price when billing federal healthcare programs. Instead, the government claimed higher prices were submitted, resulting in overpayments by taxpayer-funded programs. These are not new issues, as you may remember previous settlements by CVS and Walgreens for the same violations.
Why does this matter?
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
Keep Substitution Straight with Januvia Generics
Multiple generic sitagliptin products were recently approved for Januvia via Abbreviated New Drug Applications (ANDA) with marketing start dates as early as January 2026. You may recall that an existing sitagliptin product has already been available on the market as the New Drug Application (NDA) Authorized Generic (AG) for Zituvio.
In the past, we’ve received inquiries regarding substitution of Januvia, Zituvio, and sitagliptin. These new ANDA approvals are likely to cause…
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
NEW – Dexcom Authorized Distributors List!!!
Dexcom is a healthcare company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. The company recently updated its Suppliers webpage to include a list of authorized distributors for its products.
Pharmacies should …
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
Controlled Substance Annotations – Will Your Clinical Notes ‘PAAS’ an Onsite Audit?
PAAS National® saw onsite audits rise nearly 20% in 2025 and 2026 shows no sign of letting up. While desk and onsite audits often target similar prescriptions, onsite audits have different risk factors, including when it comes to controlled substance prescriptions.
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips:
Audit Alert: Overbilling Practices That Put Pharmacies at Risk
PBM audits have unfortunately become a regular part of pharmacy operations. These audits not only take up significant time for pharmacy staff, but they can also lead to expensive recoupments if pharmacies aren’t vigilant. While audits are often presented as necessary for compliance with contractual, billing, and documentation requirements, independent pharmacies know that PBMs will find any excuse to recoup money paid.
One common discrepancy PAAS National® analysts see…
Did you know there is much more to your audit assistance membership than just help with audits? The PAAS Member Portal contains a wealth of information and resources to assist you with audits and member service questions. Below is a list of 6 pages found on the Audit Assistance section of the PAAS Member Portal to assist you and your pharmacy staff to be proactive when it comes to audits.
PAAS Tips: